Long-term study of mexiletine in young children with myotonic disorders
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study follows children under 6 years old with genetic myotonic disorders who are taking or may take mexiletine. It helps doctors understand how well the medicine works and if it is safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 6 years old.
- A doctor has confirmed the diagnosis of a genetic myotonic disorder (like myotonic dystrophy).
- Your child has muscle stiffness or trouble relaxing muscles (e.g., hand grip myotonia, leg stiffness).
- Your child is already taking mexiletine or the doctor is considering starting it.
- No major heart problems that would make mexiletine unsafe.
- No serious liver or other health issues that might interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This trial compares a new extended-release (PR) form of mexiletine to the immediate-release (IR) form in people with non-dystrophic myotonias. The goal is to see if the longer-acting version works as well or better with fewer side effects.
This study looks at how to best measure muscle health and function in children with myotonic dystrophy. It may help prepare for future treatment trials.
This study looks at measurements and child-focused outcomes in babies and toddlers with myotonic dystrophy type 1 (DM1) that started in the newborn period. It may help researchers better track how the condition affects children and evaluate care plans more accurately.
This trial studies how safe and effective tideglusib is for children and young adults with congenital or childhood-onset myotonic dystrophy type 1 (DM1). It may help researchers learn whether the medicine improves symptoms while tracking side effects closely.
Hear when a new Myotonic Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.